Business
Hardman Research: De-risking Moderna's partnership
Hardman Research: De-risking Moderna's partnership.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 4860E Avacta Group PLC 08 May 2017 \n\nHardman Research: De-risking of the partnership with Moderna\nDe-risking of the partnership with Moderna: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. Moderna was the first to enter into an agreement with Avacta to use the Affimer technology, in tandem with Moderna's mRNA drug delivery platform. Moderna has just disclosed Phase I trial data for its mRNA technology which is the first public evidence that it works, which meaningfully de-risks the partnership plans to deliver Affimer therapeutics using mRNA \nPlease click here for the full report:\nhttp://hardmanandco.com/docs/default-source/company-docs/avacta-documents/08.05.17-de-risking-of-the-partnership-with-moderna.pdf\n\n\n\n\nTo contact us:\nHardman & Co\n11/12 Tokenhouse Yard \nLondon\nEC2R 7AS\n\n\nContacts:\nDr Martin Hall\[email protected]\nDr Dorothea Hill\[email protected]\nDr Gregoire Pave\[email protected]\nTelephone: +44 20 7929 3399\nFollow us on Twitter @HardmanandCo\n\n\n\n\nwww.hardmanandco.com \nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth ...